Given the positive local genetic correlation between CD/UC with SLE in the region harboring the JAK2 variant, patients with comorbid CD/UC and SLE may uniquely benefit from therapeutics targeting the JAK-STAT pathway, though this requires further study and investigation. The gene discussed is JAK2; the disease is systemic lupus erythematosus.